Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Broncho-Vaxom response to inhaled lipopolysaccharide-induced airway inflammation
ISRCTN25212012Phase 2Completed
- Sponsor
- OM Pharma
- Start
- Aug 2012
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of OM-85 in bronchitis, sponsored by OM Pharma. Primary endpoint: Change from baseline in total IgA in saliva after 4 weeks of treatment. Started Aug 2012; status: completed.
02
Drugs
OM-85
03
Conditions
bronchitis
Beyond the preview
Go deeper on ISRCTN25212012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN25212012.